比较1型糖尿病与2型糖尿病合并慢性肾脏病人群:基于FINE-ONE与FIDELITY人群的视角
本文综述1型糖尿病(T1D)与2型糖尿病(T2D)合并慢性肾脏病(CKD)人群在流行病学、病理生理和临床发现上的异同,探讨以白蛋白尿作为桥接生物标志物将T2D的临床证据外推至T1D。FINE-ONE试验正在T1D合并CKD人群中研究非奈利酮,以6个月尿白蛋白/肌酐比值较基线变化为主要终点和桥接生物标志物。
要点
- 尽管接受肾素-血管紧张素系统抑制剂联合血压和血糖控制的标准治疗,T1D合并CKD患者仍存在CKD进展的残余风险。
- 白蛋白尿可作为桥接生物标志物,将T2D合并CKD的临床证据外推至T1D合并CKD人群。
核心结论
- 白蛋白尿作为桥接生物标志物的概念可能为缩小T1D与T2D合并CKD人群之间治疗可及性差距提供有前景的策略,并解决T1D合并CKD患者未满足的治疗需求。
研究设计与样本
- 综述文章,讨论T1D与T2D合并CKD人群在流行病学、病理生理和临床发现上的异同,并探讨白蛋白尿作为桥接生物标志物的应用。
- FINE-ONE试验正在T1D合并CKD人群中研究非奈利酮,以6个月尿白蛋白/肌酐比值较基线变化为主要终点和桥接生物标志物。
- FIDELITY是两项非奈利酮大型3期临床试验中T2D合并CKD个体的汇总数据集。
主要发现
- 尽管接受肾素-血管紧张素系统抑制剂联合血压和血糖控制的标准治疗,T1D合并CKD患者仍存在CKD进展的残余风险。
- FINE-ONE试验人群与FIDELITY人群之间的相似性可能有助于将非奈利酮在T2D合并CKD人群中的临床证据转化至T1D合并CKD人群。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is a common comorbidity of both type 1 diabetes (T1D) and type 2 diabetes (T2D) and is associated with increased mortality, end-stage kidney disease and cardiovascular disease risk. Despite standard-of-care treatment with renin-angiotensin system inhibitors added to blood pressure and glycaemic control, people with CKD and T1D have a residual risk of CKD progression. Advances in therapeutic management have been limited over the past 3 decades, especially compared with CKD in T2D, for which new treatment options have emerged in the last 5 years. In this review article we discuss the similarities and differences between T1D and T2D populations with CKD, including epidemiology, pathophysiology and clinical findings. Additionally, we explore the use of albuminuria as a potential bridging biomarker to extrapolate clinical evidence from one population to the other. This concept could offer a promising strategy to narrow the gap in treatment availability between these populations and address the unmet therapeutic need in people with CKD and T1D. The FINE-ONE trial is investigating the non-steroidal mineralocorticoid receptor antagonist finerenone in a population with CKD and T1D using the change in urine albumin:creatinine ratio from baseline over 6 months as its primary endpoint and bridging biomarker. Similarities between the populations from FINE-ONE trial and FIDELITY (a pooled dataset of individuals with CKD and T2D included in two large phase 3 clinical trials of finerenone) may inform the translation of clinical evidence on finerenone from people with CKD and T2D to those with CKD and T1D.
引用
- Heerspink HJL, Agarwal R, Amor AJ, et al. Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations. Nephrol Dial Transplant. 2026. PMID: 40971788. doi:10.1093/ndt/gfaf183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。